Incidence and risk factors for dupilumab associated ocular adverse events: a real‐life prospective study
- 10 June 2020
- journal article
- research article
- Published by Wiley in Journal of the European Academy of Dermatology and Venereology
- Vol. 35 (1) , 172-179
Abstract
Background: Dupilumab is approved for use in moderate‐to‐severe atopic dermatitis (AD) and as an add‐on maintenance treatment in patients suffering from severe asthma with type 2 inflammation. Ocular adverse events (OAEs) have been reported with dupilumab almost exclusively in patients treated for AD.Objectives: The objectives of this study were to describe the incidence and nature of dupilumab‐induced OAEs and to assess the potential predisposing factors.Patients and methods: We conducted a prospective, single‐centre, real‐life study in adult AD patients treated with dupilumab, who were systematically examined by an ophthalmologist before and during treatment.Results: Forty‐six patients were included prospectively with a median age of 41.1 years and a median initial SCOring Atopic Dermatitis of 46.0 (IQR: 34.5–55.5). OAEs concerned 34.8% of patients and were mostly of mild to moderate severity. Two patients had to discontinue treatment due to OAE. The majority of patients developed or aggravated dry eye disease, with superficial punctate keratitis (SPK). Six patients developed conjunctivitis. Dupilumab‐induced OAEs were associated with the following pre‐existing parameters: dry eye disease with SPK (Odds ratio (OR); 6.3 [95% confidence interval (CI): 1.3–31.6]), eyelid eczema (OR: 8.7 [95%CI: 1.8–40.6]), history of food allergy (OR 3.8 (95% CI: 1.002–14,070) and IgE serum level> 1000 kU/L (OR:10.6 [CI 95%: 1.2–91.3]).Conclusion: Atopic dermatitis patients with eyelid eczema or dry eye disease symptoms may be referred to an ophthalmologist before starting dupilumab to consider initiating preventive eye hydration measures. Further multicentric and translational studies are warranted to better explain OAEs pathophysiology.Keywords
This publication has 45 references indexed in Scilit:
- Dupilumab Treatment in Adults with Moderate-to-Severe Atopic DermatitisNew England Journal of Medicine, 2014
- Atopic keratoconjunctivitis: A reviewJournal of the American Academy of Dermatology, 2014
- Assessment of clinical signs of atopic dermatitis: A systematic review and recommendationJournal of Allergy and Clinical Immunology, 2013
- Dupilumab in Persistent Asthma with Elevated Eosinophil LevelsNew England Journal of Medicine, 2013
- Atopic keratoconjunctivitis and atopic dermatitisCurrent Opinion in Allergy and Clinical Immunology, 2010
- Immunopathogenesis of ocular allergy: a schematic approach to different clinical entitiesCurrent Opinion in Allergy and Clinical Immunology, 2007
- The differences of tear function and ocular surface findings in patients with atopic keratoconjunctivitis and vernal keratoconjunctivitisAllergy, 2007
- Dermatology Life Quality Index (DLQI)-a simple practical measure for routine clinical useClinical and Experimental Dermatology, 1994
- Severity Scoring of Atopic Dermatitis: The SCORAD IndexDermatology, 1993
- OUTFLOW OF TEARS AND ITS INFLUENCE ON TEAR SECRETION AND BREAK UP TIME (B. U. T.)Acta Ophthalmologica, 1977